Orbimed Advisors LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.85 - $16.83 $8.44 Million - $14.4 Million	856,600 Added 462.03%	1,042,000 $15.1 Million
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $1.51 Million - $2.8 Million	185,400 New	185,400 $1.82 Million
Q2 2020 Aug 14, 2020	SELL	$6.75 - $12.89 $2.84 Million - $5.42 Million	-420,641 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.8 - $18.56 $1.51 Million - $4.83 Million	260,100 Added 162.01%	420,641 $3.22 Million
Q4 2019 Feb 14, 2020	BUY	$10.31 - $17.81 $1.26 Million - $2.17 Million	121,808 Added 314.48%	160,541 $2.86 Million
Q3 2019 Nov 14, 2019	BUY	$11.6 - $21.67 $449,302 - $839,344	38,733 New	38,733 $449,000
Q2 2019 Aug 14, 2019	SELL	$18.44 - $30.89 $1.67 Million - $2.8 Million	-90,500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $1.49 Million - $2.81 Million	90,500 New	90,500 $2.59 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $220M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.